MajorCalcium channel blocker, non-DHP (benzothiazepine derivative)×Antianginal – late sodium current inhibitor
Updated · Methodology
Mechanism
The liver and gut break down ranolazine mainly through the enzyme CYP3A4 and to a lesser extent through CYP2D6, and ranolazine is also a substrate of the transporter P-glycoprotein (P-gp) (ranolazine label, US Food and Drug Administration, FDA). According to its summary of product characteristics (SmPC), diltiazem is a moderate CYP3A4 inhibitor and a weak P-gp inhibitor (diltiazem SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Diltiazem 180–360 mg once daily increased steady-state ranolazine levels 1.5- to 2.4-fold in a dose-dependent way (ranolazine SmPC, European Medicines Agency, EMA). In healthy volunteers, ranolazine did not affect diltiazem pharmacokinetics (FDA). The higher the ranolazine level, the more frequent its dose-dependent adverse effects, such as nausea and dizziness, and the greater the prolongation of the heart-rate-corrected QT interval (QTc) (EMA). The Spanish diltiazem SmPC warns that diltiazem can cause QT prolongation when given with drugs that prolong the QT interval (AEMPS).
Symptoms
The rise in ranolazine levels itself causes no symptoms. Dizziness, nausea and vomiting become more frequent as the ranolazine dose rises (ranolazine summary of product characteristics, SmPC, European Medicines Agency, EMA). Abnormal coordination, myoclonus, paraesthesia and tremor have also been reported, often starting after an increase in ranolazine dose or exposure (ranolazine label, US Food and Drug Administration, FDA). QT prolongation shows only on the electrocardiogram (ECG), but feeling faint or lightheaded and an irregular or fast heartbeat may be related to it (FDA).
Management
Limit ranolazine to 500 mg twice daily in patients taking moderate CYP3A inhibitors. The US ranolazine label names diltiazem among them (ranolazine label, US Food and Drug Administration, FDA). This limit is below the maximum dose in both the US label, 1000 mg twice daily (FDA), and the European summary of product characteristics (SmPC), 750 mg twice daily (ranolazine SmPC, European Medicines Agency, EMA). According to the European SmPC, start ranolazine and increase its dose with caution in patients taking diltiazem, adjust the dose carefully and reduce it if needed (EMA). The combination itself is not contraindicated: ranolazine is an add-on to calcium antagonists when they are not enough or not tolerated (EMA). In the main trial, ranolazine was added to one of three background drugs, including diltiazem 180 mg once daily (EMA). If dizziness, nausea or vomiting occur, the ranolazine dose may need to be reduced to 500 mg or 375 mg twice daily, and if the symptoms do not resolve, stop ranolazine (EMA). Other factors can also raise ranolazine exposure, such as renal impairment with creatinine clearance of 30–80 mL/min, older age, body weight of 60 kg or less, or New York Heart Association (NYHA) class III–IV heart failure. In patients with such factors, monitor for adverse effects more often and reduce the dose or, if needed, stop ranolazine (EMA). Use ranolazine with caution with drugs that affect the heart-rate-corrected QT interval (QTc) (EMA). Combine diltiazem with QT-prolonging drugs only after a careful assessment of risks and benefits, with caution and appropriate monitoring (diltiazem SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Ranolazine extended-release tablets (Zydus Lifesciences) – prescribing information (2026)– FDA label, Zydus Lifesciences, DailyMed setid d74f3dea-7357-4e9a-be9a-2f498a44108a, version 5, 09/2026, sections 2.2, 4, 5.1, 7.1 and 7.2
- AEMPS: Ficha técnica: Diltiazem (nº registro 55285), secciones 4.4 y 4.5 (2025)– AEMPS, CIMA, Masdil 60 mg comprimidos, nº registro 55285, revisión 03/2025, secciones 4.4 y 4.5
- EMA: Ficha técnica: Ranolazina, Ranexa (EU/1/08/462), sección 4.4 (2026)– EMA, Ranexa 375 mg comprimidos de liberación prolongada (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 08462001, consultada 10/2026, sin fecha de revisión en CIMA, secciones 4.1, 4.4 y 4.5